Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index; 9 of the 20 sources its claims cite were checked for support.

Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial

Open access
Maher, Toby M, Hamblin, Mark J, Choi, Won-Il, Case, Amy Hajari, Tomos, Ioannis P, Tzouvelekis, Argyrios E, Shore, Jessica E, Bergna, Miguel A, Golod, David, Elenko, Eric, Zhang, Yanqiong, Graham, Camilla S, Song, Jin Woo, Kulkarni, Tejaswini, and the ELEVATE IPF Investigators, Maillo, Martin, Bergna, Miguel, Rojas, Ramon A, Wehbe, Luis, Cazaux, Alexis, Chirino, Alejandro, Elias, Pedro Carlos, Molinari, Luciana, Molina, Alicia, Fazio, Cristian, Kohn, Victoria, Arce, German, Raso, Ernesto, Florenzano, Matias, Miranda, Georgina, Gallegos, Juana Pavie, Orellana, Absalon Rafael Silva, Cano, Diana, Castano, Tatiana Valencia, Tchkonia, David, Vacharadze, Kakha, Katsarava, Vakhtang, Gonjilashvili, Nani, Kupreishvili, Lali, Antoniou, Katerina, Manika, Aikaterini, Tzouvelekis, Argyrios, Tomos, Ioannis, Manali, Efrosyni, Deb, Jaydip, Katiyar, Sandeep, Nath, Anjali R, Deshmukh, Hafiz, Kakkad, Tejas, Swarnakar, Rajesh, Udachankar, Gururaj, Deshmukh, Asish, Aflah, Syazatul Syakirin Sirol, Pang, Yong-Kek, Muhammad, Noorul Afidza, Razak, Megat Razeem Abdul, Ali, Irfhan Ali Hyder, Hing, Chan Tha A, Colli, Andrea, Moreno, Juan Francisco, Llamas, Francisco Sanchez, Valay, Rodolfo Posadas, Garcia, Carlos Herrera, Santiaguel, Joel, Campomanes, Mae, Dionisio, Pamela Joy, Oancea, Cristian, Davidescu, Lavinia, Cojocaru, Cristian, Dawood, Riaz Suleman, Kalla, Ismail, Mey, Larry, Van Der Linden, Michael, Williams, Paul Graham, Song, Jin Woo, Kim, Yong Hyun, Yoon, Hyoung Kyu, Kim, Eun Kyung, Choi, Hye Sook, Park, Sun Hyo, Yoo, Hongseok, Choi, Won-Il, Lee, Yongchul, Jegal, Yangjin, Jeong, Sung Hwan, Shin, Hong-Joon, Park, DongWon, Lee, Jae Ha, Park, Joo Hun, Bangpattanasiri, Kittima, Ratanawatkul, Pailin, Teerapuncharoen, Krittika, Jensen, Thomas P, Wendelberger, Barbara, Khandwala, Farah, McGlothlin, Anna, Milstone, Aaron, Singla, Abhishek, Fernandez, Juan, Hamblin, Mark, Kulkarni, Tejaswini, Lupercio, Rafael, Bregman, Benjamin, Parisi, Richard, Mageto, Yolanda, Patel, Damien, Maher, Toby, Stringer, William, Siddiqi, Ather, Johri, Shilpa, Criner, Gerard, Rankin, Bruce, Puppala, Ramana, Case, Amy, Klein, Ryan, Ramaswamy, Murali, Lancaster, Lisa, Astor, Todd, Rasheed, Ameer · 2026 · American Journal of Respiratory and Critical Care Medicine

Abstract

RATIONALE: Deupirfenidone is a strategically deuterated form of pirfenidone that retains pharmacodynamic activity but has a differentiated pharmacokinetic profile that may enable improved efficacy and favorable tolerability in patients with idiopathic pulmonary fibrosis (IPF). OBJECTIVES: To evaluate the efficacy and safety of deupirfenidone compared with placebo and pirfenidone in patients with IPF. METHODS: Patients were randomized 1:1:1:1 to deupirfenidone 550 mg TID, deupirfenidone 825 mg TID, pirfenidone 801 mg TID, or placebo. The primary endpoint was the rate of change in forced vital capacity (FVC) for the combined arms of deupirfenidone versus placebo at 26 weeks. The primary and secondary analyses used Bayesian and frequentist approaches, respectively. MEASUREMENTS AND MAIN RESULTS: A total of 257 patients with IPF were randomized, and the proportion on treatment at the end of the study was 80.0%, 68.3%, 64.6%, and 78.1% for the placebo, pirfenidone, deupirfenidone 550 mg, and deupirfenidone 825 mg arms, respectively. Posterior mean change in FVC for placebo was -110.71 mL (95% credible interval (CI), -148.75, -70.98), and for the combined deupirfenidone arms was -48.42 mL (95% CI, -87.66, -9.04) with a posterior mean difference of 62.29 mL (95% CI l, -6.13, 115.73; posterior probability, 0.985). Using a frequentist approach, the adjusted mean change in FVC for the placebo arm was -112.5 mL (95% CI, -167.2, -57.8), and for the deupirfenidone 825 mg arm was -21.5 mL (95% CI, -78.2, 35.1); the adjusted mean difference was 91.0 mL (95% CI, 12.2, 169.7; P = .02). The most common adverse events for each active treatment arm were gastrointestinal. CONCLUSIONS: In patients with IPF, treatment with deupirfenidone slowed lung disease progression over 26 weeks. TRIAL REGISTRATION: Clinicaltrials.gov number NCT05321420.

Overview

CoChat Summary

## TL;DR

ELEVATE-IPF was a 4-arm phase 2b randomized, double-blind trial in IPF that compared two doses of deupirfenidone with pirfenidone and placebo over 26 weeks. Deupirfenidone 825 mg TID slowed FVC decline versus placebo and had a safety profile similar to pirfenidone, but the study was not powered to prove superiority over pirfenidone.

## Key findings

  • 257 patients with IPF were randomized; 80.0% on placebo, 68.3% on pirfenidone, 64.6% on deupirfenidone 550 mg, and 78.1% on deupirfenidone 825 mg remained on treatment at week 26.
  • In the Bayesian primary analysis, pooled deupirfenidone reduced the 26-week decline in FVC versus placebo: -48.42 mL vs -110.71 mL, with a posterior mean difference of 62.29 mL and posterior probability of superiority of 0.985.
  • In the frequentist analysis, deupirfenidone 825 mg TID improved FVC decline versus placebo by 91.0 mL (95% CI 12.2, 169.7; P = .02); FVC percent predicted also improved by 3.00 (95% CI 0.62, 5.38; P = .01).
  • Time to IPF progression (>5% decline in FVCpp over 26 weeks or death) was delayed with deupirfenidone 825 mg TID vs placebo (HR 0.439, 95% CI 0.255, 0.756; P = .0023).
  • The most common adverse events were gastrointestinal, and grade 3 or higher TEAEs were uncommon; the paper reports 13.8% placebo, 15.9% pirfenidone, 20.0% deupirfenidone 550 mg, and 12.5% deupirfenidone 825 mg.

## Methods

  • 4-arm, randomized, double-blind, active- and placebo-controlled, dose-finding phase 2b trial across 87 sites in 14 countries.
  • Patients with IPF aged ≥40 years were randomized 1:1:1:1 to deupirfenidone 550 mg TID, deupirfenidone 825 mg TID, pirfenidone 801 mg TID, or placebo; 257 patients received at least one dose.
  • Primary endpoint was rate of decline in FVC over 26 weeks; the primary analysis used a Bayesian linear mixed-effects model with dynamic borrowing from historical placebo data, and secondary analyses used frequentist mixed models. Time-to-event outcomes used Kaplan-Meier, log-rank, and Cox regression.

## Limitations

  • The paper states the overall sample size and 26-week duration were inadequate to understand effects on secondary endpoints including hospitalizations, survival, and quality of life.
  • The study was not powered to demonstrate superiority of deupirfenidone over pirfenidone.
  • Patients with prior pirfenidone exposure were excluded and background nintedanib was not permitted, which may limit generalizability; this is stated in the paper.
  • Evident from the text: missing 26-week data, especially in the pirfenidone arm due to deaths, may have affected analyses; the paper says this “may have impacted analyses.”

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/ajrccm/aamag155

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Study design. HRCT = High resolution computed tomography; FVC = Forced vital capacity; FEV1 = Forced expiratory volume during the first second; TID—three times daily; FAS = Full analysis set (all randomized participants who received at least one dose of study drug and had at least one valid efficacy assessment after baseline)
Figure 1 Study design. HRCT = High resolution computed tomography; FVC = Forced vital capacity; FEV1 = Forced expiratory volume during the first second; TID—three times daily; FAS = Full analysis set (all randomized participants who received at least one dose of study drug and had at least one valid efficacy assessment after baseline)CC BY · PubMed Central
Figure 2 Changes from baseline over 26 weeks for A. FVC by bayesian analysis; B. FVCpp by bayesian analysis; C. FVC by frequentist analysis; and D. FVCpp by frequentist analysis. FVC = forced vital capacity; FVCpp = percent of predicted value; SE = standard error; TID = 3 times daily. Posterior mean (SE) by Bayesian approach is estimated based on a random coefficient regression model with absolute FVC (A) or FVCpp (B) over time, including baseline, as a response, and fixed effects for treatment (placebo or pooled deupirfendione 550 mg and deupirfenidone 825 mg), week, and treatment by week interaction, as well as participant-level random effects for the intercept and slope. Adjusted mean (SE) by frequentist approach is estimated based on a random coefficient regression model with absolute FVC (C) or FVCpp (D) over time, including baseline, as a response, and fixed effects for treatment (placebo, pirfenidone, deupirfenidone mg or deupirfenidone 825 mg), week, and treatment by week interaction, as well as participant-level random effects for the intercept and slope.
Figure 2 Changes from baseline over 26 weeks for A. FVC by bayesian analysis; B. FVCpp by bayesian analysis; C. FVC by frequentist analysis; and D. FVCpp by frequentist analysis. FVC = forced vital capacity; FVCpp = percent of predicted value; SE = standard error; TID = 3 times daily. Posterior mean (SE) by Bayesian approach is estimated based on a random coefficient regression model with absolute FVC (A) or FVCpp (B) over time, including baseline, as a response, and fixed effects for treatment (placebo or pooled deupirfendione 550 mg and deupirfenidone 825 mg), week, and treatment by week interaction, as well as participant-level random effects for the intercept and slope. Adjusted mean (SE) by frequentist approach is estimated based on a random coefficient regression model with absolute FVC (C) or FVCpp (D) over time, including baseline, as a response, and fixed effects for treatment (placebo, pirfenidone, deupirfenidone mg or deupirfenidone 825 mg), week, and treatment by week interaction, as well as participant-level random effects for the intercept and slope.CC BY · PubMed Central

Verification

Claims the paper makes

7 Valid · 2 Not valid · 3 Not checked · 60 Own results and interpretations

36 more claims

Create a free account to see all 72 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 13

Create a free account to see these claims.

Citations

Cites

Show all 19 references

Cited by

See all 4

Metadata

Authors
Maher, T. M., Hamblin, M. J., Choi, W.-I., Case, A. H., Tomos, I. P., Tzouvelekis, A. E., Shore, J. E., Bergna, M. A., Golod, D., Elenko, E., Zhang, Y., Graham, C. S., Song, J. W., Kulkarni, T., and the ELEVATE IPF Investigators, Maillo, M., Bergna, M., Rojas, R. A., Wehbe, L., Cazaux, A., Chirino, A., Elias, P. C., Molinari, L., Molina, A., Fazio, C., Kohn, V., Arce, G., Raso, E., Florenzano, M., Miranda, G., Gallegos, J. P., Orellana, A. R. S., Cano, D., Castano, T. V., Tchkonia, D., Vacharadze, K., Katsarava, V., Gonjilashvili, N., Kupreishvili, L., Antoniou, K., Manika, A., Tzouvelekis, A., Tomos, I., Manali, E., Deb, J., Katiyar, S., Nath, A. R., Deshmukh, H., Kakkad, T., Swarnakar, R., Udachankar, G., Deshmukh, A., Aflah, S. S. S., Pang, Y.-K., Muhammad, N. A., Razak, M. R. A., Ali, I. A. H., Hing, C. T. A., Colli, A., Moreno, J. F., Llamas, F. S., Valay, R. P., Garcia, C. H., Santiaguel, J., Campomanes, M., Dionisio, P. J., Oancea, C., Davidescu, L., Cojocaru, C., Dawood, R. S., Kalla, I., Mey, L., Van Der Linden, M., Williams, P. G., Song, J. W., Kim, Y. H., Yoon, H. K., Kim, E. K., Choi, H. S., Park, S. H., Yoo, H., Choi, W.-I., Lee, Y., Jegal, Y., Jeong, S. H., Shin, H.-J., Park, D., Lee, J. H., Park, J. H., Bangpattanasiri, K., Ratanawatkul, P., Teerapuncharoen, K., Jensen, T. P., Wendelberger, B., Khandwala, F., McGlothlin, A., Milstone, A., Singla, A., Fernandez, J., Hamblin, M., Kulkarni, T., Lupercio, R., Bregman, B., Parisi, R., Mageto, Y., Patel, D., Maher, T., Stringer, W., Siddiqi, A., Johri, S., Criner, G., Rankin, B., Puppala, R., Case, A., Klein, R., Ramaswamy, M., Lancaster, L., Astor, T., & Rasheed, A.
Affiliations
  • Imperial College, National Heart and Lung Institute , London,
  • University of Kansas Medical Center (US)
  • Piedmont Atlanta Hospital (US)
  • Sotiria General Hospital (GR)
  • Department of Respiratory Medicine, University of Patras , Patras,
  • Pulmonary Fibrosis Foundation (US)
  • Department of Research, CEMER, Florida , Vicente López,
  • PureTech (United States) (US)
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2026-04-02
Volume
212
Issue
8
Pages
1761-1769
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W7148454282
Cited by
4
References
19
Citations by year
2026: 4
FWCI
18.79
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
PureTech Health
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
pirfenidone, idiopathic pulmonary fibrosis, deuterated drugs, forced vital capacity, lung function decline, antifibrotic therapy, pharmacokinetics, drug safety, treatment tolerability, Bayesian analysis, frequentist analysis, dose comparison, medication adherence, treatment discontinuation
MeSH terms
Aged, Anti-Inflammatory Agents, Non-Steroidal, Double-Blind Method, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial. https://app.cochat.ai/papers/10.1093/ajrccm/aamag155
The paper
Maher, T. M., Hamblin, M. J., Choi, W.-I., Case, A. H., Tomos, I. P., Tzouvelekis, A. E., Shore, J. E., Bergna, M. A., Golod, D., Elenko, E., Zhang, Y., Graham, C. S., Song, J. W., Kulkarni, T., and the ELEVATE IPF Investigators, Maillo, M., Bergna, M., Rojas, R. A., Wehbe, L., . . . Rasheed, A. (2026). Deupirfenidone compared with pirfenidone and placebo in idiopathic pulmonary fibrosis (ELEVATE-IPF): a phase 2b randomized placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1093/ajrccm/aamag155

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.